87 related articles for article (PubMed ID: 33305293)
21. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
Kyrgidis A; Tzellos T; Mocellin S; Apalla Z; Lallas A; Pilati P; Stratigos A
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010307. PubMed ID: 25978975
[TBL] [Abstract][Full Text] [Related]
22. Current staging and prognostic factors in melanoma.
Bartlett EK; Karakousis GC
Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.
Pruessmann W; Rytlewski J; Wilmott J; Mihm MC; Attrill GH; Dyring-Andersen B; Fields P; Zhan Q; Colebatch AJ; Ferguson PM; Thompson JF; Kallenbach K; Yusko E; Clark RA; Robins H; Scolyer RA; Kupper TS
Nat Cancer; 2020 Feb; 1(2):197-209. PubMed ID: 33305293
[TBL] [Abstract][Full Text] [Related]
24. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
26. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.
Esmaeli B; Rubin ML; Xu S; Goepfert RP; Curry JL; Prieto VG; Ning J; Tetzlaff MT
Am J Surg Pathol; 2019 Dec; 43(12):1701-1710. PubMed ID: 31425167
[TBL] [Abstract][Full Text] [Related]
27. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
28. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.
Nagarajan P; Curry JL; Ning J; Piao J; Torres-Cabala CA; Aung PP; Ivan D; Ross MI; Levenback CF; Frumovitz M; Gershenwald JE; Davies MA; Malpica A; Prieto VG; Tetzlaff MT
Clin Cancer Res; 2017 Apr; 23(8):2093-2104. PubMed ID: 27864417
[No Abstract] [Full Text] [Related]
29. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
30. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.
Rosato PC; Wijeyesinghe S; Stolley JM; Nelson CE; Davis RL; Manlove LS; Pennell CA; Blazar BR; Chen CC; Geller MA; Vezys V; Masopust D
Nat Commun; 2019 Feb; 10(1):567. PubMed ID: 30718505
[TBL] [Abstract][Full Text] [Related]
31. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Yusko E; Vignali M; Wilson RK; Mardis ER; Hodi FS; Horak C; Chang H; Woods DM; Robins H; Weber J
Cancer Immunol Res; 2019 Mar; 7(3):458-465. PubMed ID: 30635271
[TBL] [Abstract][Full Text] [Related]
32. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.
Scheper W; Kelderman S; Fanchi LF; Linnemann C; Bendle G; de Rooij MAJ; Hirt C; Mezzadra R; Slagter M; Dijkstra K; Kluin RJC; Snaebjornsson P; Milne K; Nelson BH; Zijlmans H; Kenter G; Voest EE; Haanen JBAG; Schumacher TN
Nat Med; 2019 Jan; 25(1):89-94. PubMed ID: 30510250
[TBL] [Abstract][Full Text] [Related]
33. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Immunotherapy: Next-Generation Biomarkers.
Hogan SA; Levesque MP; Cheng PF
Front Oncol; 2018; 8():178. PubMed ID: 29896449
[TBL] [Abstract][Full Text] [Related]
35. Bystander CD8
Simoni Y; Becht E; Fehlings M; Loh CY; Koo SL; Teng KWW; Yeong JPS; Nahar R; Zhang T; Kared H; Duan K; Ang N; Poidinger M; Lee YY; Larbi A; Khng AJ; Tan E; Fu C; Mathew R; Teo M; Lim WT; Toh CK; Ong BH; Koh T; Hillmer AM; Takano A; Lim TKH; Tan EH; Zhai W; Tan DSW; Tan IB; Newell EW
Nature; 2018 May; 557(7706):575-579. PubMed ID: 29769722
[TBL] [Abstract][Full Text] [Related]
36. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
[TBL] [Abstract][Full Text] [Related]
37. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
[TBL] [Abstract][Full Text] [Related]
38. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Gershenwald JE; Scolyer RA; Hess KR; Sondak VK; Long GV; Ross MI; Lazar AJ; Faries MB; Kirkwood JM; McArthur GA; Haydu LE; Eggermont AMM; Flaherty KT; Balch CM; Thompson JF;
CA Cancer J Clin; 2017 Nov; 67(6):472-492. PubMed ID: 29028110
[TBL] [Abstract][Full Text] [Related]
39. Whole-genome landscapes of major melanoma subtypes.
Hayward NK; Wilmott JS; Waddell N; Johansson PA; Field MA; Nones K; Patch AM; Kakavand H; Alexandrov LB; Burke H; Jakrot V; Kazakoff S; Holmes O; Leonard C; Sabarinathan R; Mularoni L; Wood S; Xu Q; Waddell N; Tembe V; Pupo GM; De Paoli-Iseppi R; Vilain RE; Shang P; Lau LMS; Dagg RA; Schramm SJ; Pritchard A; Dutton-Regester K; Newell F; Fitzgerald A; Shang CA; Grimmond SM; Pickett HA; Yang JY; Stretch JR; Behren A; Kefford RF; Hersey P; Long GV; Cebon J; Shackleton M; Spillane AJ; Saw RPM; López-Bigas N; Pearson JV; Thompson JF; Scolyer RA; Mann GJ
Nature; 2017 May; 545(7653):175-180. PubMed ID: 28467829
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
